Monoclonal B lymphocytosis: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 15: | Line 15: | ||
<font color="navy">'''1. Flow cytometry defined features:'''</font> | <font color="navy">'''1. Flow cytometry defined features:'''</font> | ||
*Evidence that there is a monoclonal population of B lymphocytes (this can be based on their light chain retriction or abnormal phenotype features) | *Evidence that there is a '''monoclonal population of B lymphocytes''' (this can be based on their light chain retriction or abnormal phenotype features) | ||
*A profile of flow | *A profile of by '''flow cytometry that suggests either CLL or other LPD''', based on the abnormal gated population that may be a minority of cells | ||
*A count of abnormal cells that is <1x10<sup>9</sup> for the abnormal poulation ( | *A '''count of abnormal cells that is <1x10<sup>9</sup> for the abnormal poulation''' (usually calculated from the gated abnormal poulation and the absolute lymphocyte count | ||
<font color="navy">'''2. '''Additional clinical evidence''' that there is no significant tissue disease:'''</font> | |||
*No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells | *No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells |
Revision as of 16:01, 18 June 2023
Monoclonal B-lymphocytosis (MBL) as a distinct entity recognised in the WHO Classification and used to denote the presence of abnormal conal B-cells that do not meet the diagnostic criteria for CLL or other LPD based. It is an important distinction since affected individaual are not regarded as having a lymphoproliferative disorder, although they may experience some symptoms, and the disease may progress.
The diagnosis is suggested from flow cytometry of blood, but always requires clinical confirmation - it is important that reports reflect the need for additional clinical conformation.
Diagnosis is made from blood assessment by flow cytometry and is based on the following criteria:
1. Flow cytometry defined features:
- Evidence that there is a monoclonal population of B lymphocytes (this can be based on their light chain retriction or abnormal phenotype features)
- A profile of by flow cytometry that suggests either CLL or other LPD, based on the abnormal gated population that may be a minority of cells
- A count of abnormal cells that is <1x109 for the abnormal poulation (usually calculated from the gated abnormal poulation and the absolute lymphocyte count
2. Additional clinical evidence that there is no significant tissue disease:
- No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells
- No other features suggesting an active B-lymphoproliferative disease or lymphoma